Kartik Konduri, MD
Single-agent and combination immunotherapy continue to show positive results in patients with non–small cell lung cancer (NSCLC), especially those who have biomarker-driven disease.
In an interview during the meeting, he shared insight on these molecular developments, recently presented or discussed clinical trials, and steps the field needs to take to continue moving in a biomarker-driven paradigm of NSCLC treatment.
OncLive: What is important to note in how the field is changing regarding biomarkers?
: The lung cancer landscape is changing and, as we go about on a day-to-day basis, we are finding new discoveries about how patients are potentially noted to have markers that can be utilized for treatment. Some of them can be molecular markers, where you are utilizing targeted therapies, and there are circumstances where secondary mutations of resistance mutations occur. Resistances can occur in the form of escape mechanisms or amplifications of the target, and new drugs have come out, which potentially can be evaluated for treatment.
... to read the full story